ACC14

ACC14
April 01, 2014
For Peter Libby, MD, chief of cardiology at Brigham & Women's Hospital in Boston and professor of medicine at Harvard Medical School, the rewards of a life in clinical research outweigh the risks.
April 01, 2014
Metformin, the go-to drug for patients diagnosed with type 2 diabetes mellitus (T2DM), may help control glycated hemoglobin (A1C) levels, but it does not help prevent heart failure in heart attack patients who do not have the disease, according to a new study from the Netherlands.
April 01, 2014
Bariatric surgery has more powerful long-term effects on controlling type 2 diabetes mellitus (T2DM) that medical therapy alone, according to the largest, long-term study comparing methods.
March 31, 2014
Should patients with moderately elevated levels of triglycerides be treated, even while cardiologists await the results of a trial that may provide a definitive answer?
March 31, 2014
The triple aim promised by healthcare reform-better quality care, greater patient satisfaction, at a lower cost-will play out procedure by procedure, as physicians find ways to deliver better care and find savings.
March 31, 2014
Evidence linking sugar-sweetened sodas to cardiovascular damage has been the subject of studies presented by the American Diabetes Association and even on 60 Minutes. Now, diet sodas are getting their turn.
March 30, 2014
Wendell Primus, PhD, the veteran legislative aide for US House Minority Leader Nancy Pelosi, D-California, got right to the point when he asked those gathered for the 63rd Scientific Sessions of the American College of Cardiologists if, so far, the Affordable Care Act (ACA) was helping them, as opposed to their patients.
March 30, 2014
From a session called How to Navigate the Maze of Pharmacotherapy in Diabetes? to oral abstracts and posters, the relationship between cardiac risks and rising incidence of type 2 diabetes mellitus received plenty of attention Saturday at the 63rd Scientific Sessions of the American College of Cardiology, being held in Washington, DC.
March 30, 2014
Results from 3 phase 3 studies unveiled Saturday showed that investigational treatment for hyperlipidemia, evolocumab, significantly lowered low-density lipoprotein (LDL) cholesterol, that the results were sustained over time, and that the drug was well-tolerated without neurological side effects that are of concern to US Food and Drug Administration.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!